Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare diseases
Pfizer made a splash this week with its plans to spend $500 million on Covid-19 research. But the pharma giant isn’t letting a pandemic interfere with the M&A it needs to fulfill its longterm mission.
In fact, the outbreak may even lend them a hand in finding clinical-stage assets for the pipeline — if only the biotech execs and boards they approach fully understand the position they’re in.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.